logo
episode-header-image
Jul 2024
38m 48s

Rerun: Lars Fruergaard Jørgensen CEO of ...

Norges Bank Investment Management
About this episode
tail spinning
Up next
Sep 4
Friday Wrap-Up: Leadership Longevity and Nicolai's biggest regret
In this week's Friday Wrap-Up, Marthe Skaar sits down with Nicolai Tangen for a debrief on the podcast episode with the CEO of John Deere, news about the fund and the markets, and what's on Nicolai’s agenda for the weekend. Nicolai reflects on what surprised him most from the con ... Show More
14m 32s
Sep 2
John Deere CEO: Farming's Future, Autonomous Tractors and AI in the Field
What does farming look like when the tractor drives itself? Nicolai Tangen sits down with John May, CEO of John Deere, to explore how a 190-year-old tractor maker became one of the most advanced technology companies in agriculture. They discuss AI-powered computer vision that cut ... Show More
38m 7s
Aug 28
Friday Wrap-Up: A Hedge Fund Legend and Reflections on the Global AI Race
Introducing a brand-new podcast series: The Friday Wrap-Up! Tables have turned. Marthe Skaar, Chief of Communications and External Relations at NBIM, sits down with Nicolai Tangen, for a debrief on the latest podcast episode, news about the fund and the markets, and life behind t ... Show More
12m 55s
Recommended Episodes
Jan 2024
Novo Nordisk (Ozempic)
Last year Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, overtook LVMH to become Europe’s most valuable company. And the pull for Acquired to finally tackle healthcare (18% of US GDP!) became too strong for us to resist. While we didn’t know much about ... Show More
3h 35m
Jan 2024
JP Morgan Healthcare Conference Highlights
Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” i ... Show More
26m 16s
Sep 2023
2. The drug behind Europe's most valuable company
How much harm has been done by decades of governments investing too little? Is buy-now-pay-later causing misery or joy for young shoppers? Are supermarkets cutting prices fast enough? Is Novo Nordisk’s anti obesity wonder drug Semaglutide the most important pharmaceutical discove ... Show More
56m 39s
Feb 2024
The Ozempic economy
The weight loss drug is so profitable that its parent company, Danish health care giant Novo Nordisk, is propping up Denmark’s entire economy. It’s poised to transform America’s too. This episode was produced by Victoria Chamberlin edited by Jolie Myers, fact-checked by Kim Eggle ... Show More
25m 53s
Nov 2018
Tariffs Driving Some Production Back To China: Volvo CEO
Volvo CEO Hakan Samuelsson, on why they’re at the LA Auto show without any cars on the stand, the global demand cycle for autos, and thoughts on GM. Frans Muller, President & CEO of Ahold Delhaize, on consolidation in the U.S., the growth of online, and changing consumer food hab ... Show More
31m 45s
Dec 2023
Pfizer’s Second Gut Punch Shows Pitfalls of Weight-Loss Pills
 Bloomberg News Health Reporter Madison Muller explains how Pfizer’s second weight-loss setback this year is a warning sign that breaking into the lucrative obesity market isn’t going to be easy. Cory Klippsten, CEO at Swan Bitcoin, shares his crypto outlook for 2024. Benjamin Wo ... Show More
42m 33s
Aug 2025
Deep Dive: Novo Nordisk & Eli Lilly Stumble Into Next Phase of Ozempic Era
Two pharma giants, Eli Lilly and Novo Nordisk, are in a high-stakes race for leadership in the $150 billion GLP-1 obesity drug market. We examine Lilly’s latest earnings, the mixed results from its oral pill orforglipron, and Novo’s push with higher-dose oral semaglutide. We also ... Show More
11m 3s
Jul 2023
Ro CEO Zach Reitano on the Weight Loss Revolution
On this episode, Dan Nathan sits down with Zachariah Reitano, co-founder and CEO of Ro, to discuss the Ro origin story (2:00), weight-loss medications like Ozempic or Wegovy (11:00), Dan’s Ro Body experience (25:00), drug shortages (35:00), oral alternatives (45:00) and how these ... Show More
54m 34s
Sep 2023
Moderna CEO Talks New Drugs
Moderna CEO Stephane Bancel talks about the Moderna vaccine, drug prices, and future of the company with Bloomberg's Paul Sweeny and Matt Miller. See omnystudio.com/listener for privacy information. 
9m 22s